Does my patient still have cancer after surgery? Is there a high risk of it returning?1
Completely transform the way you see what’s next, now.
Guardant Complete is a portfolio of revolutionary liquid and tissue tests that span the cancer care continuum, all with the convenience of a single testing partner.1-5
Testing at all stages of cancer can improve patient outcomes.
See how Guardant Complete can help answer critical questions throughout the patient care journey.
What treatment is best for my newly
diagnosed patient?2,3
Is my patient responding
to treatment?4,6
What are the next treatment options for my progressing patient?4,7
More oncologists choose Guardant.
Here’s why.
Our tests are designed to meet the highest standards, because confidence in your testing partner means full confidence in your patient’s care.
Clinical Utility
Demonstrates a clear patient benefit or improves outcomes
Analytical Validation
Utilizes advanced and reliable technology to prove test performance and sensitivity
Clinical Validation
Rigorously validated to meet high standards in clinical practice
Turnaround Times
Provides fast results for timely decisions8
Access
Offers strong insurance coverage, regulatory approval, and financial assistance options
Explore some of the 1000+ publications and abstracts backing our tests.
Exceptional cancer care is more than just testing.
Get to know the power
behind Guardant tests.
Only Guardant Infinity™ unlocks both genomic and epigenomic insights to deliver the most complete view of cancer.9
Experience the #1 rated
customer support.
Get comprehensive support at every step, including on-demand medical experts, financial assistance, and mobile phlebotomy services.
MRD, minimal residual disease.
References: 1. Guardant Health data on file. October 19, 2023. Guardant Health, Inc. Redwood City, CA. 2. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. February 2023. 3. Guardant360 TissueNextTM Assay Specifications. Guardant Health, Inc. Redwood City, CA. 4. Guardant360® Assay Specifications. October 14, 2024. Guardant Health, Inc. Redwood City, CA. 5. Guardant360 ResponseTM: Guide to Ordering Guardant360 Response. Guardant Health, Inc. Redwood City, CA. 6. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047 7. Cui W, Milner-Watts C, O’Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012 8. Guardant Health data on file. September 27, 2024. Guardant Health, Inc. Redwood City, CA. 9. Guardant Health data on file. April 1, 2024. Guardant Health, Inc. Redwood City, CA.